Table 2 Subgroup analyses of antiviral treatment for ATLL.
| Â | Response Rate, Proportion [95% CI] | Â | |
|---|---|---|---|
Treatment | OR | CR | PR |
AZT-IFN alone | 0.47 [0.25; 0.69] | 0.41 [0.20; 0.66] | 0.25 [0.18; 0.33] |
AZT-IFN used in front-line regimens | 0.68 [0.52; 0.80] | 0.34 [0.25; 0.44] | 0.36 [0.30; 0.43] |
AZT-IFN used for treating aggressive ATLL (acute, lymphomatous) | 0.58 [0.45; 0.70] | 0.25 [0.20; 0.31] | 0.32 [0.26; 0.39] |
AZT-IFN used for treating indolent ATLL (chronic, smoldering) | 0.86 [0.71; 0.94] | 0.53 [0.28; 0.76] | 0.37 [0.22; 0.54] |